Zobrazeno 1 - 4 of 4 pro vyhledávání: '"Jamie Feng"'
1
Akademický článek
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
Autor: Carlos Torrado, MD, Jamie Feng, MD, FRCPC, Elizabeth Faour, MD, FRCPC, Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100647- (2024)
MET exon 14 skipping mutation has emerged as a new oncogenic driver in NSCLC with available targeted therapies, including Food and Drug Administration–approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be
Externí odkaz: https://doaj.org/article/6cb5c25c876146da8e6a27f8f44f1830
Zobrazit plný text záznamu
2
Akademický článek
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Autor: Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky
Publikováno v: Current Oncology, Vol 30, Iss 8, Pp 7499-7507 (2023)
Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective
Externí odkaz: https://doaj.org/article/abc42c904bd04f11bcc54c5692ead44a
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje